FY2024 EPS Forecast for Immix Biopharma Reduced by Analyst

Immix Biopharma, Inc. (NASDAQ:IMMX) – Equities researchers at HC Wainwright lowered their FY2024 earnings estimates for shares of Immix Biopharma in a report issued on Monday, January 6th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.87) per share for the year, down from their prior forecast of ($0.67). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.85) EPS.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08).

Immix Biopharma Price Performance

IMMX stock opened at $2.25 on Thursday. The business’s 50-day moving average is $2.01 and its two-hundred day moving average is $1.95. The firm has a market capitalization of $61.89 million, a P/E ratio of -2.65 and a beta of 0.27. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $6.67.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immix Biopharma stock. Geode Capital Management LLC lifted its stake in Immix Biopharma, Inc. (NASDAQ:IMMX) by 5.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,082 shares of the company’s stock after buying an additional 7,954 shares during the period. Geode Capital Management LLC owned approximately 0.55% of Immix Biopharma worth $224,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.